Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Forestview on Jan 11, 2021 9:22am

Not a good sign

When both Marky and Mugsy are disappointed.  :(

But, maybe 3B has a point.  Nothing has changed with the science.  What we got here were soe vague details and some delays (which are covid driven).  If the FDA application happens in a matter of weeks, let's say end of Feb, and it's approved by early Q2 (is that possible?) then we should see a spike.  In the end, the IP is sound.  We all know that.  Nothing's changed there.

I do wonder though if we will have see buy outs in the billions.  I may need to temper my expectations and re work my retirement model to something more realistic.  Dan doesn't seem to be aggressive from that perspective.  

Stay long.  I've been in this for two years, and doubled my position over the last six months.  I'm not selling, I'm just going to be less optimistic.
Comment by MrMugsy on Jan 11, 2021 9:30am
Well ... the partnering is still on track ... from what I can see.  That's the wild card.  Anything can happen here. We have some delay which shouldn't be a surprise but it isn't ideal for the product plan (OTENA). More questions than answers if you've been here a while ... that's all ... hahaha ... 
Comment by Straylight on Jan 11, 2021 10:04am
Price hitting $4.10 early in the day so that's a start. I'm trying to keep an open mind for the release, if you're deep into this then it didn't really move the needle much but if you put this in front of new institutional investors its still a compelling story. Patience is key, I know we have all heard that before though...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities